<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02758925</url>
  </required_header>
  <id_info>
    <org_study_id>2015-005837-37</org_study_id>
    <nct_id>NCT02758925</nct_id>
  </id_info>
  <brief_title>CyBeR Association in Relapsed/Refractory DLBCL</brief_title>
  <acronym>CyBeR-Lymph</acronym>
  <official_title>Phase 2 Study of Cytarabine in Association With Bendamustine and Rituximab in the Treatment of Relapsed/Refractory Diffuse Large B Cell Lymphoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Caen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Caen</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Forty percent of patients with diffuse large B cell lymphoma (DLBCL) have primary refractory
      or relapsed disease (R/R). For these fit patients, standard treatment in second line therapy
      is high dose therapy with autologous stem cell transplantation (ASCT). In 48% of DLBCL no
      ASCT is possible due to progressive disease. For these patients or ineligible to
      transplantation patients, salvage therapy is often rituximab-gemcitabine-oxaliplatine regimen
      with an overall response rate (ORR) about 50%.

      Bendamustine in combination with rituximab, used as a single agent in the setting of R/R
      DLBCL patients, have shown an ORR of 62.7% and 45.8% with a good safety profile.

      Bendamustine and cytarabine (BAC) showed high synergy in inducing cell death in mantle cell
      lymphoma and DLBCL cell lines. In a recent phase II study, the combination of cytarabine with
      Rituximab and Bendamustine (R-BAC) in patients with mantle cell lymphoma who were previously
      untreated, refractory or relapsed was evaluated.

      The efficacy and safety of the R-BAC association will be evaluated in this phase II trial
      enrolling 78 patients with relapsed or refractory DLBCL.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Participants will received 6 cycles every 21 days with a follow-up period of 24 months.

      CT-Scan after 3 cycles and at the end of the treatment will be used to assess treatment
      response, established with Cheson criteria in 1999.

      Principal objective is to obtain an overall response rate of 60% (corresponding to an
      increased of 15% of the rituximab-gemcitabine-oxaliplatine regimen's overall response rate).

      Secondaries objectives are to value toxicity, progression free survival and overall survival.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>June 2016</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">November 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>treatment response</measure>
    <time_frame>up to 20 weeks (at the end of the treatment)</time_frame>
    <description>established with 1999 Cheson criteria on CT-scan</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>overall survival</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>progression free survival</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">78</enrollment>
  <condition>Diffuse Large B Cell Lymphoma</condition>
  <arm_group>
    <arm_group_label>DLBCL patients</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>they will receive a combination of: Rituximab 375mg/m2 IV at Day 1 Bendamustine 90mg/m2 IV at Day 1 and 2 Cytarabine 1000mg/m2 IV at day 2 every 21 days for 6 cycles</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rituximab</intervention_name>
    <description>375mg/m2 IV day 1</description>
    <arm_group_label>DLBCL patients</arm_group_label>
    <other_name>mabthera</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bendamustine</intervention_name>
    <description>90mg/m2 IV day 1-2</description>
    <arm_group_label>DLBCL patients</arm_group_label>
    <other_name>levact</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cytarabine</intervention_name>
    <description>1000mg/m2 or 750mg/m2 at day 2 if patients aged more than 70 years or toxicity grade 3/4</description>
    <arm_group_label>DLBCL patients</arm_group_label>
    <other_name>aracytine</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. patients from 18 to 75 years

          2. Patient sharpened the social security system

          3. Patients with relapsed or refractory diffuse large B cell lymphoma who received at
             least one prior line of immunochemotherapy unfit for intensive regimen therapy and
             autologous stem cell transplantation (ASCT) eligible patients to stem cell
             transplantation with failure of the salvage therapy patients with relapse after ASCT

          4. Not previously treated with bendamustine

          5. WHO performance status 0, 1 or 2

          6. Adequate hematological function as defined by: leucocyte count ≥ 3.0 109/L, platelet
             count ≥ 75 109/L

          7. Females of childbearing potential must agree to have a medically acceptable method of
             contraception from study treatment initiation until the end of treatment.

          8. Signed informed consent.

        Exclusion Criteria:

          1. Person under guardianship or curatorship , or unable to understand the purpose of the
             study

          2. Central nervous system or meningeal involvement

          3. WHO performance status more than 2

          4. Contraindication to any drug contained in the chemotherapy regimen

          5. HIV disease, active hepatitis B or C

          6. Any serious active disease or co-morbid medical condition

          7. Any of the following laboratory abnormalities.

               -  Leucocyte count &lt; 3.0 x 109/L

               -  Platelet count &lt; 75 x 109/L

          8. Any serious medical condition, laboratory abnormality, or psychiatric illness that
             would prevent the subject from signing the informed consent form.

          9. Pregnant or lactating females.

         10. Prior history of malignancies, other than lymphoma, unless the patient has been free
             of the disease for ≥ 3 years. Exceptions include the following:

               -  Basal cell carcinoma of the skin.

               -  Squamous cell carcinoma of the skin.

               -  Carcinoma in situ of the cervix.

               -  Carcinoma in situ of the breast.

               -  Incidental histological finding of prostate cancer (TNM stage of T1a or T1b).

         11. renal impairment with an estimated (modified dietin renal disease; MDRD) creatinine
             clearance &lt; 40 ml/min,

         12. chronic liver disease or day-1 (AST/ALT )≥2.5 upper limit of normal (ULN), total
             bilirubin≥1.5 ULN,
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gandhi Damaj, PHD</last_name>
    <role>Study Director</role>
    <affiliation>University Hospital, Caen</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Emilie Reboursiere, MD</last_name>
    <phone>+33231272140</phone>
    <email>reboursiere-e@chu-caen.fr</email>
  </overall_contact>
  <reference>
    <citation>Ohmachi K, Niitsu N, Uchida T, Kim SJ, Ando K, Takahashi N, Takahashi N, Uike N, Eom HS, Chae YS, Terauchi T, Tateishi U, Tatsumi M, Kim WS, Tobinai K, Suh C, Ogura M. Multicenter phase II study of bendamustine plus rituximab in patients with relapsed or refractory diffuse large B-cell lymphoma. J Clin Oncol. 2013 Jun 10;31(17):2103-9. doi: 10.1200/JCO.2012.46.5203. Epub 2013 May 6.</citation>
    <PMID>23650408</PMID>
  </reference>
  <reference>
    <citation>Castegnaro S, Visco C, Chieregato K, Bernardi M, Albiero E, Zanon C, Madeo D, Rodeghiero F. Cytosine arabinoside potentiates the apoptotic effect of bendamustine on several B- and T-cell leukemia/lymphoma cells and cell lines. Leuk Lymphoma. 2012 Nov;53(11):2262-8. doi: 10.3109/10428194.2012.688200. Epub 2012 May 21.</citation>
    <PMID>22530665</PMID>
  </reference>
  <reference>
    <citation>Vacirca JL, Acs PI, Tabbara IA, Rosen PJ, Lee P, Lynam E. Bendamustine combined with rituximab for patients with relapsed or refractory diffuse large B cell lymphoma. Ann Hematol. 2014 Mar;93(3):403-9. doi: 10.1007/s00277-013-1879-x. Epub 2013 Aug 17.</citation>
    <PMID>23955074</PMID>
  </reference>
  <reference>
    <citation>Visco C, Finotto S, Pomponi F, Sartori R, Laveder F, Trentin L, Paolini R, Di Bona E, Ruggeri M, Rodeghiero F. The combination of rituximab, bendamustine, and cytarabine for heavily pretreated relapsed/refractory cytogenetically high-risk patients with chronic lymphocytic leukemia. Am J Hematol. 2013 Apr;88(4):289-93. doi: 10.1002/ajh.23391. Epub 2013 Feb 28.</citation>
    <PMID>23450436</PMID>
  </reference>
  <reference>
    <citation>Visco C, Finotto S, Zambello R, Paolini R, Menin A, Zanotti R, Zaja F, Semenzato G, Pizzolo G, D'Amore ES, Rodeghiero F. Combination of rituximab, bendamustine, and cytarabine for patients with mantle-cell non-Hodgkin lymphoma ineligible for intensive regimens or autologous transplantation. J Clin Oncol. 2013 Apr 10;31(11):1442-9. doi: 10.1200/JCO.2012.45.9842. Epub 2013 Feb 11.</citation>
    <PMID>23401442</PMID>
  </reference>
  <results_reference>
    <citation>Mounier N, El Gnaoui T, Tilly H, Canioni D, Sebban C, Casasnovas RO, Delarue R, Sonet A, Beaussart P, Petrella T, Castaigne S, Bologna S, Salles G, Rahmouni A, Gaulard P, Haioun C. Rituximab plus gemcitabine and oxaliplatin in patients with refractory/relapsed diffuse large B-cell lymphoma who are not candidates for high-dose therapy. A phase II Lymphoma Study Association trial. Haematologica. 2013 Nov;98(11):1726-31. doi: 10.3324/haematol.2013.090597. Epub 2013 Jun 10.</citation>
    <PMID>23753028</PMID>
  </results_reference>
  <verification_date>May 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 14, 2016</study_first_submitted>
  <study_first_submitted_qc>April 29, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 3, 2016</study_first_posted>
  <last_update_submitted>May 3, 2016</last_update_submitted>
  <last_update_submitted_qc>May 3, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 4, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Hospital, Caen</investigator_affiliation>
    <investigator_full_name>Emilie REBOURSIERE</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, B-Cell</mesh_term>
    <mesh_term>Lymphoma, Large B-Cell, Diffuse</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rituximab</mesh_term>
    <mesh_term>Cytarabine</mesh_term>
    <mesh_term>Bendamustine Hydrochloride</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

